Cat. No. 3997
Chemical Name: 6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1
Biological ActivityReceptor-selective acetylenic retinoid; binds at retinoid acid receptors (RAR) -β and -γ. Topically used for the treatment of skin disorders, particularly psoriasis and acne. Implicated in the treatment of basal cell carcinomas; induces upregulation of Bax in vivo. Exhibits antiproliferative and proapoptotic activity. Upregulates TIGs (Tazarotene-induced genes), including the cell adhesion molecule TIG1 and the tumor-suppressor TIG3.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Son et al (2009) Expression and mutation analysis of TIG1 (Tazarotene-induced gene 1) in human gastric cancer. Oncol.Res. 17 571. PMID: 19806788.
Orlandi et al (2004) Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with Tazarotene. J.Invest.Dermatol. 122 1037. PMID: 15102095.
Higuchi et al (2003) Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lungcarcinoma cells and its association with suppression of the transformed phenotype. Oncogene 22 4627. PMID: 12879006.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Tazarotene from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Tazarotene, supplier, receptor-selective, retinoid, RARbeta, RARgamma, retinoic, acid, receptor, treats, skin, conditions, Tocris Bioscience, Retinoic Acid Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Synthetic retinoid; induces differentiation of stem cellsSI-2 hydrochloride
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonistSR 9009
Rev-Erbα/β agonistSR 9238
Potent and selective LXR inverse agonist
December 13 - 15, 2016